ATE331507T1 - Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung - Google Patents

Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung

Info

Publication number
ATE331507T1
ATE331507T1 AT04712898T AT04712898T ATE331507T1 AT E331507 T1 ATE331507 T1 AT E331507T1 AT 04712898 T AT04712898 T AT 04712898T AT 04712898 T AT04712898 T AT 04712898T AT E331507 T1 ATE331507 T1 AT E331507T1
Authority
AT
Austria
Prior art keywords
sphingolipid
present
safingol
pharmaceutical composition
composition containing
Prior art date
Application number
AT04712898T
Other languages
German (de)
English (en)
Inventor
Barry James Maurer
Patrick C Reynolds
Rao B Vishnuvajjala
Shanker Gupta
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of ATE331507T1 publication Critical patent/ATE331507T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739Lipopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04712898T 2003-02-21 2004-02-19 Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung ATE331507T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44953603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
ATE331507T1 true ATE331507T1 (de) 2006-07-15

Family

ID=32927531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712898T ATE331507T1 (de) 2003-02-21 2004-02-19 Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung

Country Status (9)

Country Link
US (1) US7476692B2 (enExample)
EP (1) EP1594488B1 (enExample)
JP (2) JP4842800B2 (enExample)
AT (1) ATE331507T1 (enExample)
CA (1) CA2516399C (enExample)
DE (1) DE602004001393T2 (enExample)
ES (1) ES2270347T3 (enExample)
MX (1) MXPA05008860A (enExample)
WO (1) WO2004075834A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007233155B2 (en) 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
JP2013510878A (ja) * 2009-11-12 2013-03-28 テキサス テック ユニバーシティー 高増殖性障害を処置する組成物および方法
EP3024441A4 (en) * 2013-07-25 2017-04-19 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
IT201600105201A1 (it) * 2016-10-19 2018-04-19 Nutrilinea Srl Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche
US10034895B2 (en) * 2017-11-30 2018-07-31 Joel Steven Goldberg Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
WO1997014412A1 (en) * 1994-08-26 1997-04-24 Mary Kay Inc. Topically applied, structural cellulite treatments
US5635536A (en) * 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
ATE409486T1 (de) * 1998-06-29 2008-10-15 Children S Hospital Los Angele Behandlung hyperproliferativer erkrankungen
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
JP3220434B2 (ja) * 1998-12-28 2001-10-22 花王株式会社 化粧料
KR100343885B1 (ko) * 1999-07-20 2002-07-19 주식회사 두산 파이토스핑고신의 수용액의 제조 방법
KR100371491B1 (ko) * 1999-07-27 2003-02-07 주식회사 두산 피부 보호용 크림조성물
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3896234B2 (ja) * 1999-12-24 2007-03-22 花王株式会社 化粧料
EP1287815A1 (en) * 2001-08-31 2003-03-05 Cosmoferm B.V. Use of a sphingoid base for inhibiting ceramidase activity
CN100340227C (zh) * 2001-12-10 2007-10-03 花王株式会社 神经酰胺类乳化物
JP4220698B2 (ja) * 2001-12-10 2009-02-04 花王株式会社 皮膚外用剤
JP4119646B2 (ja) * 2001-12-10 2008-07-16 花王株式会社 セラミド類乳化物の製造法
PL373235A1 (en) * 2002-09-05 2005-08-22 Galderma S.A. Solution for ungual application

Also Published As

Publication number Publication date
DE602004001393D1 (de) 2006-08-10
DE602004001393T2 (de) 2007-06-14
MXPA05008860A (es) 2005-10-05
CA2516399C (en) 2013-05-14
US20050187186A1 (en) 2005-08-25
WO2004075834A2 (en) 2004-09-10
JP4842800B2 (ja) 2011-12-21
EP1594488B1 (en) 2006-06-28
EP1594488A2 (en) 2005-11-16
JP2006518743A (ja) 2006-08-17
JP2011126886A (ja) 2011-06-30
CA2516399A1 (en) 2004-09-10
WO2004075834A3 (en) 2005-03-24
ES2270347T3 (es) 2007-04-01
US7476692B2 (en) 2009-01-13

Similar Documents

Publication Publication Date Title
DE60222573D1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
EA200400777A1 (ru) Фармацевтические композиции соединения платины
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
WO2006018221A8 (de) Lagerstabile infusionslösung von dihydropteridinonen
EP1961748A3 (en) 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
BRPI0416650A (pt) composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase
WO2003086324A3 (en) Preparation and use of a stable formulation of allosteric effector compounds
ATE331507T1 (de) Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung
RU2009102803A (ru) Пригодный для инъекции состав антибиотика и раствор для его внутреннего введения
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
MY151470A (en) Controlled release solid preparation
ATE494894T1 (de) Viruzide wirkungen von einer zubereitung enthaltend cetylpyridiniumchlorid und zitronensäure
ATE391730T1 (de) Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
EA200800370A1 (ru) Новая фармацевтическая лекарственная форма ингибитора фермента циклооксигеназы с модифицированным высвобождением
DE602005009110D1 (de) Injektierbare wässrige Paclitaxel-Lösungen und Verfahren zu ihrer Herstellung
DK1305057T3 (da) Mikropartikelformig biomaterialesammensætning af hyaluronsyre til medicinsk anvendelse
EP1552838A4 (en) RUBROFUSARIN GLYCOSIDE-CONTAINING COMPOSITION
JPH07324034A (ja) フマル酸ケトチフェン含有の点眼剤
PL1631574T3 (pl) Analogi kolchikozydowe
HUP0004701A2 (hu) Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására
EE200200599A (et) Tsüklipostiiniühend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,ühendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
SE0301947D0 (sv) New method and uses
BR0002076A (pt) Compostos 1-aza-2-alquil-6-aril-cicloalcano, um processo para sua preparação e composições farmacêuticas contendo estes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties